In Situ Hybridization (ISH) Market by Product (Consumables (Kits, Probes) Software), Technology (FISH (DNA, RNA), CISH), Application (Cancer, Infectious Disease), and End User (Diagnostic Labs, Research Institutes, CROs), Region - Global Forecast to 2025
[169 Pages Report] The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period. The increasing incidence and prevalence of cancer and genetic disorders and awareness about companion diagnostics tests in ISH are the major factors driving the growth of this market.
COVID-19 Impact on the Global ISH Market
The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the ISH market for diagnostics and research applications.
Although RT-PCR is widely used to detect and diagnose coronavirus in human samples, researchers and diagnostics companies across the globe are finding cost-effective and sensitive assay kits to deal with the pandemic. Molecular cytogenetics tests such as ISH play a role in identifying infected cells or tissue. As a result, in 2020, some companies in this market have focused on launching COVID-19 specific probes.
- A US-based firm, Creative Bioarray (US), launched a 2019 Novel Coronavirus Detection FISH Probe for the detection of viral particles in cells.
- Bio-Techne (US), is helping researchers with its RNAscope technology that allows the visualization of viral loads in cell and tissues using its V-nCoV2019-S probe.
With its applications in infectious disease diagnostics, the impact of COVID will have a short-term positive effect on the ISH market.
In Situ Hybridization Market Dynamics
Driver: Increasing incidence of genetic disorder and cancer
Over the years, there has been an increase in the incidence of cancer across the globe. Extensive studies conducted over the last two decades related to human diseases have recognized recurrent genomic abnormalities as potential driving factors for a variety of cancers. Cytogenetic assays such as ISH help in integrating IHC and DNA FISH to complete the in situ toolset for researchers to discover, develop, and implement new-generation diagnostic procedures. The direct imaging of gene expression in situ at the RNA level delivers a unique insight into the interplay between cancer cells and the tumor microenvironment while the cancer is in progression.
According to GLOBOCAN, cancer affected 43.8 million people and caused 9.6 million deaths in 2018. Globally, around one in every six deaths is caused by cancer. In addition, there were 18.1 million new cases in 2018. The incidence of cancer can increase up to 29.5 million, with a mortality rate of 16.5 million in 2040.
With regard to genetic disorders, as per the research conducted by McMaster University (Canada), the prevalence of hemophilia has tripled to reach 1,125,000, as compared to previous estimates of 400,000. The most affected countries include Canada, France, Italy, the UK, Australia, and New Zealand. This increase is likely to impact the growth of the in situ hybridization market.
Challenge: Lack of skilled professionals
To conduct an ISH-based test, it is very crucial to understand the molecular information of a chromosome or a gene. In addition, the reluctance to move from manual operations to automation is another challenge for market growth. Many providers find it challenging to make the transition to IT-based approaches from manual or traditional methods, or may not prefer to make the shift at all. Thus, the shortage of skilled, well-trained, and technically knowledgeable laboratory technicians to conduct ISH-based diagnosis is limiting their overall adoption, particularly in emerging markets.
Opportunity: Untapped markets in developing countries
In developed countries, high-quality molecular diagnostic tests are readily available. However, in developing countries, the cost of these diagnostic technologies is very high, which often makes them unaffordable for a large part of the population. Moreover, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in developing countries.
As a result, emerging markets such as India, China, Brazil, offer significant growth opportunities for MDx-based technology (including ISH) owing to the rising geriatric population, the growing prevalence of infectious diseases and various types of cancers, improving healthcare infrastructure, and increasing investments by respective government bodies and leading players in these countries.
By product, the consumables segment accounted for the largest share of the ISH market in 2019.
Based on the product, the ISH market is segmented into consumables, instruments, and software. Based on the product, the ISH market is segmented into consumables, instruments, and software & services. In 2019, the consumables segment accounted for the largest share of the ISH market. The growth of this segment is attributed to the availability of a wide range of kits & reagents, the growing use of reagents in research and diagnostic devices, and the need for reliable, specific, and rapid detection of cancer and genetic disorders in the early stages.
By application, the cancer diagnostic segment accounted for the largest share of the ISH market in 2019.
Based on application, the ISH market is segmented broadly into cancer diagnostics, cytology, infectious disease diagnostics, neuroscience, and immunology. The cancer diagnostics segment accounted for the largest share of the global market. This can be attributed to the high demand of FISH in the detection of cellular and genetic markers in cancers such as HER2, ALK, and ROS.
North America accounted for the largest share of the global ISH market in 2019.
In 2019, North America accounted for the largest share of the ISH market. The increasing incidence of cancer and infectious diseases in the region is driving the focus on the development of personalized medicine and diagnostics tests. As a result, due to the strong demand for early cancer detection capabilities, the market for ISH-based diagnostic tests is expected to see steady growth. In addition, the region is home to a large base of clinical research laboratories and academic institutes.
Key Players
Some of the key players include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), Thermofisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US)
Scope of the report
|
Report Metric |
Details |
|
Market Size Available for Years |
20182025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
20202025 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product, Application, End User, Technology and Region |
|
Geographies Covered |
North America, Europe, APAC and the RoW |
|
Companies Covered |
The major market players include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies (US), Danaher (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US) |
The study categorizes the ISH market into the following segments and subsegments:
By Product
- Consumables
- Kits & Reagents
- Probes
- Accessories
- Instruments
- Software
By Technology
- FISH
- DNA FISH
- RNA FISH
- PNA FISH
- CISH
By Application
- Cancer Diagnostics
- Cytology
- Infectious Disease Diagnostics
- Neuroscience
- Immunology
By End User
- Hospitals & Diagnostic Laboratories
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- CROs
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Rest of the World
- Latin America
- The Middle East and Africa
Recent Developments
- In 2020, RNAscope ISH Detection Kit (Bio-Techne) received CE-IVD approval for BOND-III platform (Leica Biosystems )
- In 2020, Creative Bioarray (US) launched 2019 Novel Coronavirus Detection FISH probes to detect viral particles in infected cells & tissues.
- In 2019, Roche launched VENTANA HER2 Dual ISH DNA Probe Cocktail assay
- In 2019, Roche provided its platform for integration with Bio-Technes RNAscope ISH assay.
- In 2019, Agilent Technologies, the National University of Singapore, and the National University Hospital set up Singapores first integrated R&D facility.
Frequently Asked Questions (FAQ):
What is the growth rate of the global in situ hybridization market?
The growth rate of the global in situ hybridization market is expected to be 7.4% during the forecast period.
Who are the leading players in the in situ hybridization market?
Some of the leading players in the ISH market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US)
Who are the major end-users of the in situ hybridization market?
The end user of the ISH market includes hospitals & diagnostics laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and CROs.Hospitals & diagnostics laboratories are the largest end-users in the ISH market.
What are the major technologies in the ISH market?
By technology, the ISH is segmented into FISH and CISH. The FISH segment is furthered categorized into DNA, RNA, and PNA FISH. In 2019, the DNA FISH accounted for the largest share in the ISH market
What are the major applications in the ISH market?
By application, the ISH is segmented into cancer diagnostics, cytology, infectious disease diagnostics, neuroscience, and immunology. The cancer diagnostics accounted for the largest share in the ISH market. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 30)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 1 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET
2.2 MARKET DATA ESTIMATION & TRIANGULATION
FIGURE 2 DATA TRIANGULATION METHODOLOGY
2.3 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 4 IN SITU HYBRIDIZATION MARKET SIZE (USD BILLION)
FIGURE 5 IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2020−2025)
FIGURE 6 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS AND OPPORTUNITIES
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 36)
FIGURE 7 IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2019
FIGURE 8 FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2019
FIGURE 9 IN SITU HYBRIDIZATION MARKET, BY END USER: MARKET RANKING OF SEGMENTS, BY MARKET SIZE
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IN SITU HYBRIDIZATION MARKET
4 PREMIUM INSIGHTS (Page No. - 39)
4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW
FIGURE 11 RISING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING DISEASE INCIDENCE WILL FAVOR MARKET GROWTH
4.2 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SHARE, BY END USER AND COUNTRY (2019)
FIGURE 12 HOSPITAL & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2019
4.3 IN SITU HYBRIDIZATION MARKET, BY PRODUCT
FIGURE 13 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET
4.4 IN SITU HYBRIDIZATION MARKET SHARE, BY TECHNOLOGY, 2020 VS. 2025
FIGURE 14 FLUORESCENCE IN SITU HYBRIDIZATION HOLDS THE LARGEST SHARE OF THE MARKET, BY TECHNOLOGY
4.5 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 15 KITS & REAGENTS SEGMENT ACCOUNT FOR THE LARGEST MARKET SHARE
5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing incidence of genetic disorders and cancer
5.2.1.2 Awareness about companion diagnostics
5.2.2 OPPORTUNITIES
5.2.2.1 Untapped markets in developing countries
5.2.3 CHALLENGES
5.2.3.1 Lack of skilled professionals
5.3 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
5.4 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE IN SITU HYBRIDIZATION MARKET
6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT (Page No. - 47)
6.1 INTRODUCTION
TABLE 1 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
6.2 CONSUMABLES
TABLE 2 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 3 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 4 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 5 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 6 APAC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.2.1 KITS & REAGENTS
6.2.1.1 Increasing focus on companion diagnostics has driven market demand for kits & reagents
TABLE 7 IN SITU HYBRIDIZATION KITS & REAGENTS MARKET, BY REGION, 20182025 (USD MILLION)
6.2.2 PROBES
6.2.2.1 Preference for direct localization of DNA/RNA sequences using probes is likely to drive the market
TABLE 8 IN SITU HYBRIDIZATION PROBES MARKET, BY REGION, 20182025 (USD MILLION)
6.2.3 ACCESSORIES
TABLE 9 IN SITU HYBRIDIZATION ACCESSORIES MARKET, BY REGION, 20182025 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 NEED FOR AUTOMATED SYSTEMS SUPPORTS MARKET GROWTH
TABLE 10 IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 11 NORTH AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 12 EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 13 APAC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.4 SOFTWARE
6.4.1 DEMAND FOR SOFTWARE IS DRIVEN BY THE NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS
TABLE 14 IN SITU HYBRIDIZATION SOFTWARE MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 15 NORTH AMERICA: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 16 EUROPE: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 17 APAC: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 20182025 (USD MILLION)
7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY (Page No. - 56)
7.1 INTRODUCTION
TABLE 18 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
7.2 FLUORESCENCE IN SITU HYBRIDIZATION
TABLE 19 FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 20 FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 21 NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 22 EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 23 APAC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
7.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION
7.2.1.1 Need to ensure the stability of genetic material likely to drive the market
TABLE 24 DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 25 NORTH AMERICA: DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 26 EUROPE: DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 27 APAC: DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
7.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION
7.2.2.1 Rise in biomedical research activity has supported market growth
TABLE 28 RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 29 NORTH AMERICA: RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 30 EUROPE: RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 31 APAC: RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
7.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION
7.2.3.1 Increased application in infectious disease resulted in market growth
TABLE 32 PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 33 NORTH AMERICA: PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 34 EUROPE: PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 35 APAC: PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
7.3 CHROMOGENIC IN SITU HYBRIDIZATION
7.3.1 COST-EFFECTIVENESS OVER FLUORESCENCE IN SITU HYBRIDIZATION FISH SUPPORTS MARKET GROWTH
TABLE 36 CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 37 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 38 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 39 APAC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION (Page No. - 66)
8.1 INTRODUCTION
TABLE 40 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.2 CANCER DIAGNOSTICS
8.2.1 INCREASING IMPORTANCE IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
TABLE 41 IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 20182025 (USD MILLION)
TABLE 42 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 43 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 44 APAC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 20182025 (USD MILLION)
8.3 CYTOLOGY
8.3.1 FISH IS PREFERRED IN THE DETECTION OF CHROMOSOMAL ABNORMALITIES
TABLE 45 IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 20182025 (USD MILLION)
TABLE 46 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 20182025 (USD MILLION)
TABLE 47 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 20182025 (USD MILLION)
TABLE 48 APAC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 20182025 (USD MILLION)
8.4 INFECTIOUS DISEASE DIAGNOSTICS
8.4.1 NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DIAGNOSIS IS LIKELY TO SUPPORT MARKET GROWTH
TABLE 49 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 20182025 (USD MILLION)
TABLE 50 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 51 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 52 APAC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 20182025 (USD MILLION)
8.5 NEUROSCIENCE
8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS HAS BOOSTED OVERALL R&D ACTIVITY
TABLE 53 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 20182025 (USD MILLION)
TABLE 54 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 20182025 (USD MILLION)
TABLE 55 EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 20182025 (USD MILLION)
TABLE 56 APAC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 20182025 (USD MILLION)
8.6 IMMUNOLOGY
8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES SUPPORTS MARKET GROWTH
TABLE 57 IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 20182025 (USD MILLION)
TABLE 58 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 20182025 (USD MILLION)
TABLE 59 EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 20182025 (USD MILLION)
TABLE 60 APAC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 20182025 (USD MILLION)
9 IN SITU HYBRIDIZATION MARKET, BY END USER (Page No. - 76)
9.1 INTRODUCTION
TABLE 61 IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
9.2 HOSPITAL & DIAGNOSTIC LABORATORIES
9.2.1 DEMAND FOR MOLECULAR TESTS TO DRIVE MARKET GROWTH
TABLE 62 IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 20182025 (USD MILLION)
TABLE 63 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 64 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 65 APAC: IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 20182025 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 INCREASING RESEARCH ON CHROMOSOMAL ABNORMALITIES WILL SUPPORT MARKET GROWTH
TABLE 66 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 20182025 (USD MILLION)
TABLE 67 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 68 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 69 APAC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 20182025 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 NEED TO DEVELOP PRECISION TREATMENTS DRIVES DEMAND FOR IN SITU HYBRIDIZATION
TABLE 70 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 20182025 (USD MILLION)
TABLE 71 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 72 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 73 APAC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20182025 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 74 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 20182025 (USD MILLION)
TABLE 75 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 76 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 77 APAC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20182025 (USD MILLION)
10 IN SITU HYBRIDIZATION MARKET, BY REGION (Page No. - 85)
10.1 INTRODUCTION
FIGURE 18 IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 78 IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 19 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 79 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 80 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 81 NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 82 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 83 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 84 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025(USD MILLION)
TABLE 85 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.2.1 US
10.2.1.1 Government funding for life science research drives the market growth in the US
TABLE 86 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 87 US: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 88 US: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 89 US: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 90 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 91 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Investments by the Canadian government and non-profit organizations for innovation are likely to boost the market
TABLE 92 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 93 CANADA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 94 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 95 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 96 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 97 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.3 EUROPE
TABLE 98 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 99 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 100 EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 101 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 102 EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 103 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 104 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany accounted for the largest share of the European market
TABLE 105 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 106 GERMANY: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 107 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 108 GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 109 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 110 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Increased investments in proteomics and genomics are likely to fuel the growth of ISH technology
TABLE 111 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 112 FRANCE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 113 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 114 FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 115 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 116 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.3.3 UK
10.3.3.1 Increasing focus on cancer research in the UK is a key market growth driver
TABLE 117 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 118 UK: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 119 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 120 UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 121 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 122 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.3.4 REST OF EUROPE
TABLE 123 ROE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 124 ROE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 125 ROE: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 126 ROE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 127 ROE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 128 ROE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 20 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 129 APAC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 130 APAC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 131 APAC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 132 APAC: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 133 APAC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 134 APAC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 135 APAC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Focus on personalized diagnostics products to support market growth in Japan
TABLE 136 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 137 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 138 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 139 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 140 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 141 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.4.2 CHINA
10.4.2.1 China forms the fastest-growing market in the APAC
TABLE 142 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 143 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 144 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 145 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 146 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 147 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Collaborations between hospitals and diagnostics labs will propel market growth in India
TABLE 148 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 149 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 150 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 151 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 152 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 153 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 154 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 155 ROAPAC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 156 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 157 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 158 ROAPAC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 159 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 160 ROW: IN SITU HYBRIDIZATION MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 161 ROW: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 162 ROW: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 163 ROW: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 164 ROW: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 165 ROW: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 166 ROW: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Growing cancer screening programs will propel market growth in Latin America
TABLE 167 LATAM: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 168 LATAM: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 169 LATAM: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 170 LATAM: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 171 LATAM: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 172 LATAM: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Infrastructural development is expected to contribute to the growth of the MEA market
TABLE 173 MEA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 174 MEA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 175 MEA: IN SITU HYBRIDIZATION MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 176 MEA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 177 MEA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 178 MEA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 20182025 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 126)
11.1 INTRODUCTION
11.2 MARKET RANKING ANALYSIS
FIGURE 21 COMPANY RANKING IN THE IN SITU HYBRIDIZATION MARKET, 2019
11.3 MARKET EVALUATION FRAMEWORK
TABLE 179 MARKET EVALUATION FRAMEWORK: AGREEMENT & PRODUCT LAUNCHTHE MAJOR STRATEGY ADOPTED BY PLAYERS
11.4 COMPETITIVE SCENARIO
11.4.1 KEY PRODUCT LAUNCHES
11.4.2 KEY COLLABORATIONS & AGREEMENTS
11.4.3 KEY EXPANSIONS
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 128)
12.1 OVERVIEW
12.2 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX
12.2.1 STARS
12.2.2 EMERGING LEADERS
12.2.3 PERVASIVE COMPANIES
12.2.4 EMERGING COMPANIES
FIGURE 22 GLOBAL IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX, 2019
12.3 COMPANY PROFILES
12.3.1 ABBOTT LABORATORIES
FIGURE 23 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
12.3.2 F. HOFFMANN-LA ROCHE
FIGURE 24 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019)
12.3.3 AGILENT TECHNOLOGIES
FIGURE 25 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019)
12.3.4 THERMO FISHER SCIENTIFIC
FIGURE 26 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
12.3.5 BIO-TECHNE CORPORATION
FIGURE 27 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2019)
12.3.6 QIAGEN N.V.
FIGURE 28 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
12.3.7 DANAHER CORPORATION
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
12.3.8 PERKINELMER
FIGURE 30 PERKINELMER: COMPANY SNAPSHOT (2019)
12.3.9 ENZO BIOCHEM
FIGURE 31 ENZO BIOCHEM: COMPANY SNAPSHOT (2019)
12.3.10 BIO-RAD LABORATORIES
FIGURE 32 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
12.3.11 MERCK KGAA
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2019)
12.3.12 ABNOVA CORPORATION
12.3.13 BIOGENEX LABORATORIES
12.3.14 BIOCARE MEDICAL
12.3.15 OPGEN
FIGURE 34 OPGEN: COMPANY SNAPSHOT (2019)
12.3.16 BIO SB
12.3.17 GENEMED BIOTECHNOLOGIES
12.3.18 ABCAM
FIGURE 35 ABCAM: COMPANY SNAPSHOT (2019)
12.3.19 CREATIVE BIOARRAY
12.3.20 BIOCAT GMBH
12.3.21 ZYTOVISION
13 APPENDIX (Page No. - 163)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in situ hybridization market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the ISH market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as WHO, OECD, GLOBOCAN, CDC, World Bank, and World Cancer Research Fund International. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global ISH market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global in situ hybridization market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical and biopharmaceutical industry) and supply-side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across four major regionsNorth America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the ISH market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the global ISH market and other dependent submarkets.. The research methodology and the market numbers were then validated from primaries.
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the ISH market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the ISH market
Report Objectives
- To define, describe, segment, and forecast the in situ hybridization market based on product, application, end user, technology and region
- To provide detailed information about the factors influencing market growth, such as drivers, opportunities, and challenges
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall in situ hybridization market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)2
- To profile the key players in the global in situ hybridization market and comprehensively analyze their core competencies3 and market rankings
- To track and analyze competitive developments, such as product launches, expansions, and partnerships in the in situ hybridization market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the European in situ hybridization market into countries from the Rest of Europe.
- Further breakdown of the Asia Pacific in situ hybridization market into countries from the Rest of the APAC.
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Get in-depth analysis of the COVID-19 impact on the In Situ Hybridization (ISH) Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the In Situ Hybridization (ISH) Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the In Situ Hybridization (ISH) Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in In Situ Hybridization (ISH) Market